← Leaderboards
Wesley C Van Voorhis
University Of Washington
$32,631,211
Attributed
$48,316,794
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,316,794 · 14
By mechanism
R01$29,402,829 · 9
U01$11,371,703 · 1
T32$5,261,143 · 1
P01$1,784,201 · 2
D43$496,918 · 1
Top collaborators
- Michael J Gale13 shared
- Peter M Rabinowitz13 shared
- Judith N. Wasserheit13 shared
- Frederick Simmons Buckner7 shared
- Michael H Gelb7 shared
- Christophe L.M.J. Verlinde7 shared
- Ethan A Merritt5 shared
- Marilyn Parsons5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Michael H Gelb$24,827,130
- Christophe L.m.j. Verlinde$963,803
- Frederick Simmons Buckner$14,937,505
- Wilhelmus G. J. Hol$41,011,333
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionLeadAnimalsDesignProteinsPharmaceutical PreparationsPropertyBaseNovel TherapeuticsGrowthToxic EffectStructureKinase InhibitorPhosphotransferasesPre-ClinicalDrug DevelopmentPathogenIn VitroSamplingIn VivoDrug KineticsBloodParasitesPublic Health Relevance
Grant awards (79)
Optimization of Lead BKIs for Cryptosporidiosis Therapy$813,238
R01 · FY2025 · AI · contact PI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis$675,079
R01 · FY2025 · HD · contact PI
Integrated Research Training on Vector Borne Diseases in Pakistan: Vector Biology, Virology and Disease Epidemiology.$247,409
D43 · FY2025 · TW
University of Washington Arboviral Research Network (UWARN)$1,616,309
U01 · FY2024 · AI · contact PI
Optimization of Lead BKIs for Cryptosporidiosis Therapy$803,939
R01 · FY2024 · AI · contact PI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis$668,478
R01 · FY2024 · HD · contact PI
Integrated Research Training on Vector Borne Diseases in Pakistan: Vector Biology, Virology and Disease Epidemiology.$249,509
D43 · FY2024 · TW
University of Washington Arboviral Research Network (UWARN)$127,489
U01 · FY2024 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$1,609,959
U01 · FY2023 · AI · contact PI
Optimization of Lead BKIs for Cryptosporidiosis Therapy$803,979
R01 · FY2023 · AI · contact PI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis$649,614
R01 · FY2023 · HD · contact PI
University of Washington Arboviral Research Network (UWARN)$127,489
U01 · FY2023 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$44,501
U01 · FY2023 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$1,691,975
U01 · FY2022 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$1,166,044
U01 · FY2022 · AI · contact PI
Optimization of Lead BKIs for Cryptosporidiosis Therapy$809,679
R01 · FY2022 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$664,481
U01 · FY2022 · AI · contact PI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis$634,016
R01 · FY2022 · HD · contact PI
University of Washington Arboviral Research Network (UWARN)$1,640,909
U01 · FY2021 · AI · contact PI
Optimization of Lead BKIs for Cryptosporidiosis Therapy$834,465
R01 · FY2021 · AI · contact PI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis$701,303
R01 · FY2021 · HD · contact PI
University of Washington Arboviral Research Network (UWARN)$633,625
U01 · FY2021 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$176,500
U01 · FY2021 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$1,751,002
U01 · FY2020 · AI · contact PI
University of Washington Arboviral Research Network (UWARN)$121,420
U01 · FY2020 · AI · contact PI
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis$1,212,837
R01 · FY2018 · AI · contact PI
Host Defense Training in Allergy and Infectious Diseases$581,244
T32 · FY2018 · AI · contact PI
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis$353,085
R01 · FY2018 · HD · contact PI
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis$1,230,645
R01 · FY2017 · AI · contact PI
Host Defense Training in Allergy and Infectious Diseases$631,587
T32 · FY2017 · AI · contact PI
Discovery and validation of new kinase drug targets in T. brucei$407,294
R01 · FY2017 · AI
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis$358,068
R01 · FY2017 · HD · contact PI
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis$1,193,904
R01 · FY2016 · AI · contact PI
Host Defense Training in Allergy and Infectious Diseases$530,907
T32 · FY2016 · AI · contact PI
Discovery and validation of new kinase drug targets in T. brucei$404,532
R01 · FY2016 · AI
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis$338,926
R01 · FY2016 · HD · contact PI
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis$1,196,852
R01 · FY2015 · AI · contact PI
Host Defense Training in Allergy and Infectious Diseases$568,694
T32 · FY2015 · AI · contact PI
Discovery and validation of new kinase drug targets in T. brucei$404,743
R01 · FY2015 · AI
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis$375,926
R01 · FY2015 · HD · contact PI
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis$1,580,174
R01 · FY2014 · AI · contact PI
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum$988,554
R01 · FY2014 · AI · contact PI
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis$428,707
R01 · FY2014 · HD · contact PI
Host Defense Training in Allergy and Infectious Diseases$428,200
T32 · FY2014 · AI · contact PI
Discovery and validation of new kinase drug targets in T. brucei$404,853
R01 · FY2014 · AI
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum$929,801
R01 · FY2013 · AI · contact PI
Host Defense Training in Allergy and Infectious Diseases$545,936
T32 · FY2013 · AI · contact PI
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum$992,830
R01 · FY2012 · AI · contact PI
Biochemistry of Protein Prenylation$611,813
R01 · FY2012 · AI
Host Defense Training in Allergy and Infectious Diseases$507,930
T32 · FY2012 · AI · contact PI
Glycogen Synthase Kinase-3 as a drug target for Trypanosoma brucei$382,239
R01 · FY2012 · AI · contact PI
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum$1,013,092
R01 · FY2011 · AI · contact PI
Biochemistry of Protein Prenylation$613,376
R01 · FY2011 · AI
Host Defense Training in Allergy and Infectious Diseases$488,762
T32 · FY2011 · AI · contact PI
Glycogen Synthase Kinase-3 as a drug target for Trypanosoma brucei$382,239
R01 · FY2011 · AI · contact PI
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum$1,051,325
R01 · FY2010 · AI · contact PI
Biochemistry of Protein Prenylation$619,554
R01 · FY2010 · AI
HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASES$505,332
T32 · FY2010 · AI · contact PI
Glycogen Synthase Kinase-3 as a drug target for Trypanosoma brucei$386,100
R01 · FY2010 · AI · contact PI
Biochemistry of Protein Prenylation$37,986
R01 · FY2010 · AI
Biochemistry of Protein Prenylation$609,576
R01 · FY2009 · AI
HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASES$472,551
T32 · FY2009 · AI · contact PI
Glycogen Synthase Kinase-3 as a drug target for Trypanosoma brucei$390,000
R01 · FY2009 · AI · contact PI
Biochemistry of Protein Prenylation$64,992
R01 · FY2009 · AI
Biochemistry of Protein Prenylation$597,282
R01 · FY2008 · AI
Protein Production in the Medical Structural Genomics of Pathogenic Protozoa$572,213
P01 · FY2008 · AI · contact PI
Surface Antigens of Treponema pallidum$317,281
R01 · FY2008 · AI · contact PI
Protein Production in the Medical Structural Genomics of Pathogenic Protozoa$563,517
P01 · FY2007 · AI · contact PI
Surface Antigens of Treponema pallidum$323,425
R01 · FY2007 · AI · contact PI
Protein Production in the Medical Structural Genomics of Pathogenic Protozoa$501,985
P01 · FY2006 · AI · contact PI
Surface Antigens of Treponema pallidum$333,085
R01 · FY2006 · AI · contact PI
Surface Antigens of Treponema pallidum$341,100
R01 · FY2005 · AI
Surface Antigens of Treponema pallidum$341,100
R01 · FY2004 · AI
SURFACE ANTIGENS OF TREPONEMA PALLIDUM$271,753
R01 · FY2002 · AI
PROTECTIVE IMMUNITY AGAINST SYPHILIS$0
P01 · FY2002 · AI
SURFACE ANTIGENS OF TREPONEMA PALLIDUM$263,837
R01 · FY2001 · AI
PROTECTIVE IMMUNITY AGAINST SYPHILIS$0
P01 · FY2001 · AI
SURFACE ANTIGENS OF TREPONEMA PALLIDUM$256,153
R01 · FY2000 · AI
PROTECTIVE IMMUNITY AGAINST SYPHILIS$146,486
P01 · FY2000 · AI